Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2015; 04(01): 038-040
DOI: 10.4103/2278-330X.149950
Drug Review

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment

Lalit S. Raut
Department of Medicine, Leukemia/BMT Division, Vancouver General Hospital, Vancouver, British Columbia
› Author Affiliations Source of Support: Nill.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug.

Key words

CPX-351 - cytarabine - daunorubicin - Acute myeloid leukemia - liposomes


Publication History

Article published online:
31 December 2020

© 2015. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
  • 2 Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 2007;7:216-23.
  • 3 Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5:1854-63.
  • 4 Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, et al. In vivo maintenance of synergistic cytarabine: Daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009;33:129-39.
  • 5 Harasym T, Lim W, Tardi P, Xie S, Fan M, Huang R, et al. Leukemia Cell-Selective Uptake of Cytarabine (Cyt) and Daunorubicin (Daun) Mediated by CPX-351 Liposome Injection in the Bone Marrow Compartment [abstract]. Presented at the 14 th Congress of the European Hematology Association; 2009 June 4-7; Berlin, Germany. Haematologica 2009:94:1-694.
  • 6 Feldman E, Lancet J, Kolitz JE, Trang JM, Mayer L, Louie A. Pharmacology of CPX-351: A Nano-scale Liposomal Fixed Molar Ratio Cytarabine-Daunorubicin for Patients with Advanced Leukemia. Presented at the 14 th Congress of the European Hematology Association; 2009 June 4-7; Berlin, Germany. Haematologica 2009;94:1-694.
  • 7 Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, et al. First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011;29:979-85.
  • 8 Cortes JE, Feldman EJ, Goldberg SL, Rizzieri DA, Paulsen KH, Louie AC, et al. CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in 65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report. Presented at the ASH 2011 Annual Meeting; 2011 December 9-13; San Diego, CA. Blood; 2011:118.
  • 9 Lancet J, Feldman E, Cortes J, Hogge D, Kovacsovics T, Tallman M et al. Phase II b Randomized Study of CPX-351 vs. Conventional Cytarabine+Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report [abstract]. Presented at the ASH 2009 Annual Meeting; 2009 December 9-13; New Orleans, LA. Blood 2009;114.
  • 10 Lancet J, Cortes J, Kovacsovics T, Hogge D, Kolitz JE, Tallman MS, et al. CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML) [abstract]. Presented at ASCO 2011 Annual Meeting; 2011 June 3-7; Chicago, IL, USA. J Clin Oncol 2011;29.
  • 11 Cortes JE, Feldman EJ, Goldberg SL, Rizzieri DA, Louie AC, Paulsen KH, et al. Phase II B, multicenter, randomised, open-label trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus intensive salvage therapy in adult patients≤65 years old with aml in first relapse following an initial CR>1 month duration (study 205). Available from: http://www.celatorpharma.com/new/files/poster_2011_Cortes%20et%20al%20205%20ASH%202011.pdf [Last accessed on 2014 Feb 10].
  • 12 Lancet J, Feldman E, Cortes J, Hogge D, Kovacsovics T, Tallman M et al. CPX-351 Can Induce Remission in AML Immediately After Failed Induction with Cytarabine and Daunorubicin [abstract]. Presented at ASCO 2010 Annual Meeting; 2010 Jun 4-8; Chicago, IL, USA. J Clin Oncol; 2010;28.
  • 13 Tardi P, Harasym T, Dos Santos N, Lim W-S, Xie S, Ciofani T, et al. CPX-351, a liposome formulation containing a synergistic 5:1 molar ratio of cytarabine (Cyt) and daunorubicin (Daun), exhibits improved efficacy against human leukemia xenografts when administered at intermediate frequency in consolidation treatment [abstract]. Presented at the AACR 2009 Annual Meeting; 2009 April 18-22; Denver, CO: AACR; 2009.
  • 14 Gergis, Usama, Roboz, Gail J, Ritchie, Ellen, et al. A novel sequential treatment utilizing cpx-351 as salvage chemotherapy followed by a reduced intensity conditioning allogeneic stem-cell transplantation for patients with refractory leukemia. Presented at the ASH 2011 Annual Meeting; 2011 December 9-13; San Diego, CA. Blood; 2011:118.
  • 15 Feldman E, Lancet J, Kolitz JE, Hogge D, Tallman MS, Goldberg S, et al. Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy [abstract]. Presented at the ASCO 2013 Annual Meeting; 2013 May 31-June 4; Chicago. J Clin Oncol 2013;31:15.
  • 16 Goldberg S, Cortes J, Feldman EJ, Rizzleri DA, Kantarjian HM, Limor S, et al. Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigator′s choice: A subset analysis by prognostic group [abstract]. Presented at the ASCO 2012 Annual Meeting; 2012 June 1-5; Chicago, IL, USA. J Clin Oncol 2012;30:15.
  • 17 Lancet JE, Cortes JE, Kovacsovics T, Hogge D, Kolitz JE, Tallman MS, et al. The Impact of Prior Hypomethylating Agent Treatment among Secondary AML Patients Treated with CPX-351 or 7+3 Chemotherapy [abstract]. Presented at the 16 th Congress of the EHA; 2011 June 9-12; London. Haematologica 2011;96:1-773.
  • 18 Cortes JE, Feldman EJ, Goldberg SL, Rizzieri DA, Louie AC, Kolitz JE. Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy among First Relapse AML patients [abstract]. Presented at the ASH 2011 Annual Meeting; 2011 December 9-13; San Diego, CA. Blood 2011:118.
  • 19 Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01696084 [Last accessed on 2014 Feb 10].
  • 20 Tyner JW, Mayer L, Tardi P, Fletcher LB, Spurgeon SE, Kovacsovics T, et al. Evaluation of cpx-351 anti-leukemic activity against primary patient leukemia cells [abstract]. Presented at the ASH 2010 Annual Meeting; 2010 December 4-7; Orlando, FL. Blood 2010:116.